Physician profile
Mark A Cassol
NPI 1023128063
$4,920.92
in general payments reported to CMS, 2019-2025
14 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,767 · 2020: $204 · 2021: $785 · 2022: $196 · 2023: $785 · 2024: $681 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,985.07 | 2019-2024 | Tecnis Iol, Amo Phaco Needle, Veritas Vision System |
| Alcon Vision LLC | $1,460.61 | 2019-2025 | Clareon, Clareon Panoptix Pro, Centurion |
| Ivantis, INC | $324.64 | 2020-2021 | |
| Merz North America, INC. | $299.11 | 2021 | |
| Ocular Therapeutix, INC. | $187.06 | 2023-2024 | Dextenza |
| New World Medical,INC. | $168.06 | 2021-2023 | |
| Sight Sciences, INC. | $154.02 | 2019-2024 | Omni Surgical System |
| Genentech USA, INC. | $124.74 | 2023 | Vabysmo |
| Harrow Eye, LLC | $123.63 | 2024 | Vevye |
| Biotissue Holdings INC. | $39.51 | 2019-2020 | |
| Lombart Brothers, INC. | $17.18 | 2019-2020 | |
| Allergan, INC. | $16.56 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $11.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.52 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cassol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.